Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Related Articles
Hot Mulled Cider | Recipes | Cook For Your Life
Hot mulled cider is a real treat to sip, plus it is also a perfect seasonal non-alcoholic drink for holiday parties.
Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors
Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
BBC – Home
The best of the BBC, with the latest news and sport headlines, weather, TV & radio highlights and much more from across the whole of…
The Ongoing Debate: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials
Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a…
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
